We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
This Quarter
Est. Return
+5.48%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.53B
AUM Growth
+$340M
(+11%)
Cap. Flow
-$961M
Cap. Flow
% of AUM
-27.24%
Top 10 Holdings %
Top 10 Hldgs %
34.64%
Holding
91
New
15
Increased
24
Reduced
22
Closed
8
Top Buys
| 1 |
APLS
Apellis Pharmaceuticals
APLS
|
+$93.1M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$47M |
| 3 |
BCAX
Bicara Therapeutics
BCAX
|
+$42.3M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$39.9M |
| 5 |
Edgewise Therapeutics
EWTX
|
+$39M |
Top Sells
| 1 |
EXAS
Exact Sciences
EXAS
|
+$48.3M |
| 2 |
Vaxcyte
PCVX
|
+$46M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$39M |
| 4 |
Apogee Therapeutics
APGE
|
+$35.9M |
| 5 |
argenx
ARGX
|
+$35.5M |
Sector Composition
| 1 | Healthcare | 65.68% |
| 2 | Consumer Staples | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Madrigal Pharmaceuticals
MDGL
$12.7B
| $39M | 1.11% |
+183,818
| New | +$47M |
|
|
27
Vaxcyte
PCVX
$8.19B
| $34M | 0.96% |
297,568
-510,735
| -63% | -$46M |
|
28
Replimune Group
REPL
$813M
| $33.7M | 0.95% |
3,070,837
+2,057,460
| +203% | +$20.9M |
|
29
Arvinas
ARVN
$534M
| $31.6M | 0.9% |
1,284,472
+767,242
| +148% | +$20M |
|
30
Krystal Biotech
KRYS
$10.3B
| $30.7M | 0.87% |
168,691
+61,512
| +57% | +$11.9M |
|
31
OrthoPediatrics
KIDS
$507M
| $30M | 0.85% |
1,107,770
| – | – |
|
32
DexCom
DXCM
$28.1B
| $29.6M | 0.84% |
+441,086
| New | +$36.2M |
|
33
BioNTech
BNTX
$23.3B
| $29.4M | 0.83% |
+247,750
| New | +$22.8M |
|
|
FNA
34
DELISTED
Paragon 28, Inc.
FNA
| $27.6M | 0.78% |
4,135,109
-15,000
| -0.4% | -$114K |
|
35
Relay Therapeutics
RLAY
$4.25B
| $24.8M | 0.7% |
3,499,427
+492,628
| +16% | +$3.68M |
|
36
Alphatec Holdings
ATEC
$1.39B
| $22.5M | 0.64% |
4,041,065
+1,846,165
| +84% | +$14.2M |
|
37
Harrow
HROW
$1.6B
| $19.8M | 0.56% |
439,638
+142,450
| +48% | +$4.82M |
|
38
Cullinan Oncology
CGEM
$1.1B
| $19.7M | 0.56% |
1,176,173
+1,000,000
| +568% | +$17.7M |
|
|
EXAS
39
DELISTED
Exact Sciences
EXAS
| $19.5M | 0.55% |
286,178
-855,500
| -75% | -$48.3M |
|
40
Ocular Therapeutix
OCUL
$2.18B
| $19.5M | 0.55% |
2,239,770
+596,000
| +36% | +$4.91M |
|
41
Immatics
IMTX
$1.29B
| $18.8M | 0.53% |
+1,647,565
| New | +$19.5M |
|
42
Ironwood Pharmaceuticals
IRWD
$658M
| $18.3M | 0.52% |
4,438,232
| – | – |
|
43
Boston Scientific
BSX
$64B
| $15.9M | 0.45% |
+189,200
| New | +$14.9M |
|
44
Dianthus Therapeutics
DNTH
$5.46B
| $13.5M | 0.38% |
493,687
+126,836
| +35% | +$3.53M |
|
45
4D Molecular Therapeutics
FDMT
$611M
| $13.2M | 0.38% |
1,225,448
+855,990
| +232% | +$14.2M |
|
46
Celcuity
CELC
$4.46B
| $13.2M | 0.37% |
884,306
+367,663
| +71% | +$6.06M |
|
|
ORKA
47
Oruka Therapeutics
ORKA
$5.23B
| $12.6M | 0.36% |
+515,726
| New | +$17.9M |
|
48
Alector
ALEC
$167M
| $10.1M | 0.29% |
2,158,245
-222,459
| -9% | -$1.19M |
|
49
Zura Bio
ZURA
$512M
| $10M | 0.28% |
+2,472,806
| New | +$9.24M |
|
50
Insulet
PODD
$11B
| $9.89M | 0.28% |
+42,500
| New | +$8.73M |
|
Similar funds
NC
VVP
SP
DIG
ECP
PCM
ROTUOC
SM